Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease
Boletín de Información Farmacoterapéutica de Navarra · 2025
DOI: 10.54095/bitn20253202en ↗Kurz gefasst
Fachartikel in der Zeitschrift Boletín de Información Farmacoterapéutica de Navarra, 2025. Verfasst von Javier Garjón Parra.
Abstract (Originalsprache)
The control of plasma lipids, and especially LDL-C levels is one of the actions on which clinical guidelines for reducing the risk of suffering a cardiovascular event are based, especially in secondary prevention. Cardiovascular prevention starts with lifestyles: a healthy diet, weight control and physical exercise. Statins are the first line drug due to the large body of evidence demonstrating their safety and efficacy. With the advent of drugs that allow major reductions in LDL-C levels, clinical practice guidelines have gradually reduced their limits for this substance, especially in patients with established cardiovascular disease.
Zitieren
APA
Parra, J. G. (2025). Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease. Boletín de Información Farmacoterapéutica de Navarra. https://doi.org/10.54095/bitn20253202en
Vancouver
Parra JG. Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease. Boletín de Información Farmacoterapéutica de Navarra. 2025. doi:10.54095/bitn20253202en
BibTeX
@article{Parra2025,
author = {Parra, Javier Garjón},
title = {Beyond statins: evidence for other lipid-lowering drugs in patients with atherosclerotic cardiovascular disease},
journal = {Boletín de Información Farmacoterapéutica de Navarra},
year = {2025},
doi = {10.54095/bitn20253202en}
}
EUVIMED